Cue Biopharma (CUE) Competitors $0.74 -0.01 (-1.79%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.74 +0.00 (+0.65%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. CRDF, EDIT, ZYBT, DBVT, INZY, IMMP, DRUG, LRMR, TVRD, and TRDAShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Cardiff Oncology (CRDF), Editas Medicine (EDIT), Zhengye Biotechnology (ZYBT), DBV Technologies (DBVT), Inozyme Pharma (INZY), Prima BioMed (IMMP), Bright Minds Biosciences (DRUG), Larimar Therapeutics (LRMR), Tvardi Therapeutics (TVRD), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Its Competitors Cardiff Oncology Editas Medicine Zhengye Biotechnology DBV Technologies Inozyme Pharma Prima BioMed Bright Minds Biosciences Larimar Therapeutics Tvardi Therapeutics Entrada Therapeutics Cardiff Oncology (NASDAQ:CRDF) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Which has more risk & volatility, CRDF or CUE? Cardiff Oncology has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Does the media refer more to CRDF or CUE? In the previous week, Cardiff Oncology had 19 more articles in the media than Cue Biopharma. MarketBeat recorded 19 mentions for Cardiff Oncology and 0 mentions for Cue Biopharma. Cardiff Oncology's average media sentiment score of 0.54 beat Cue Biopharma's score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Overall Sentiment Cardiff Oncology Positive Cue Biopharma Neutral Do analysts rate CRDF or CUE? Cardiff Oncology currently has a consensus price target of $11.70, suggesting a potential upside of 343.18%. Cue Biopharma has a consensus price target of $4.00, suggesting a potential upside of 442.59%. Given Cue Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, CRDF or CUE? Cue Biopharma has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$680K258.29-$45.43M-$0.87-3.03Cue Biopharma$9.29M5.98-$40.67M-$0.67-1.10 Is CRDF or CUE more profitable? Cue Biopharma has a net margin of -507.87% compared to Cardiff Oncology's net margin of -9,344.14%. Cardiff Oncology's return on equity of -77.94% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-9,344.14% -77.94% -63.65% Cue Biopharma -507.87%-228.43%-114.66% Do insiders & institutionals hold more shares of CRDF or CUE? 16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by insiders. Comparatively, 10.8% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryCue Biopharma beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.56M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.1017.6228.7823.81Price / Sales5.98179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book2.638.508.275.54Net Income-$40.67M-$55.06M$3.25B$259.28M7 Day Performance-16.50%-3.99%-3.70%-4.64%1 Month Performance6.53%9.58%4.34%4.41%1 Year Performance0.99%6.70%25.90%17.95% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma3.8382 of 5 stars$0.74-1.8%$4.00+442.6%-4.9%$56.56M$9.29M-1.1060CRDFCardiff Oncology1.797 of 5 stars$3.73-6.0%$11.70+213.7%+14.3%$264.11M$587K-4.0520Trending NewsEarnings ReportInsider TradeOptions VolumeAnalyst RevisionGap UpEDITEditas Medicine3.9706 of 5 stars$2.96-6.0%$4.70+58.8%-52.5%$263.70M$32.31M-0.97230News CoverageUpcoming EarningsZYBTZhengye BiotechnologyN/A$5.75+3.6%N/AN/A$261.77M$25.53M0.00278News CoverageAnalyst UpgradeDBVTDBV Technologies3.6322 of 5 stars$9.86+4.2%$14.75+49.7%+89.6%$258.97M$4.15M-2.0080Earnings ReportAnalyst RevisionGap UpINZYInozyme Pharma2.1223 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750News CoverageUpcoming EarningsIMMPPrima BioMed1.4453 of 5 stars$1.80+4.7%$7.00+288.9%-17.1%$251.19M$5.14M0.002,021News CoverageHigh Trading VolumeDRUGBright Minds Biosciences1.6659 of 5 stars$33.86-4.5%$83.25+145.9%+2,799.1%$249.74MN/A-94.05N/AHigh Trading VolumeLRMRLarimar Therapeutics2.2629 of 5 stars$3.64-6.2%$18.50+408.2%-58.7%$248.43MN/A-2.4430Positive NewsUpcoming EarningsTVRDTvardi TherapeuticsN/A$24.87-6.2%$64.25+158.3%N/A$248.25MN/A0.0080Positive NewsTRDAEntrada Therapeutics3.2274 of 5 stars$6.23-4.7%$25.67+312.0%-63.7%$248.21M$210.78M7.69110Positive News Related Companies and Tools Related Companies Cardiff Oncology Alternatives Editas Medicine Alternatives Zhengye Biotechnology Alternatives DBV Technologies Alternatives Inozyme Pharma Alternatives Prima BioMed Alternatives Bright Minds Biosciences Alternatives Larimar Therapeutics Alternatives Tvardi Therapeutics Alternatives Entrada Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CUE Stock Alerts